Fig. 6

RAD51 expression predicts platinum sensitivity and survival of ovarian cancer. RAD51 expression was detected immunohistochemically in a cohort of 126 patients and quantified using HSCORE. The patients were subdivided into two groups: HSCORE ≤ 1.5, low expression; HSCORE > 1.5, high expression. Platinum sensitivity was defined as no recurrence within 6 months after therapy, while platinum resistance represented recurrence or relapse within 6 months. a Platinum responsiveness of ovarian cancer patients concerning RAD51 expression was analyzed (Chi-squared test). b Comparison of RAD51 expression between the platinum-sensitive group (N = 92) and the platinum-resistant group (N = 34) (Student’s t-test). Survival analysis was performed and Kaplan–Meier survival curves for OS (c) and PFS (d) were depicted (log-rank test). Correlation analysis between RAD51 expression and mean survival time of patients with the same HSCORE was performed for OS (e) and PFS (f) (Pearson’s correlation test)